These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34452444)

  • 1. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
    Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
    Li DK; Chung RT
    Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
    Suda G; Yamasaki K; Sakamoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
    Welsch C
    Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
    Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.
    Sultan A; Bane A; Braimoh G; Debes JD
    Am J Trop Med Hyg; 2020 Nov; 103(5):2083-2084. PubMed ID: 32828136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of new hepatitis C treatments in different regions of the world.
    Wei L; Lok AS
    Gastroenterology; 2014 May; 146(5):1145-50.e1-4. PubMed ID: 24662488
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 13. HCV drug resistance and DAA agents.
    Szymanek A; Krzysztof S
    Przegl Epidemiol; 2013; 67(3):403-6, 513-5. PubMed ID: 24340550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
    Ta K; Zehtabchi S
    Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.
    Costilla V; Mathur N; Gutierrez JA
    Clin Liver Dis; 2015 Nov; 19(4):641-56, vi. PubMed ID: 26466653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
    El Sherif O; Afhdal N; Curry M
    J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis.
    Villani R; Monami M; Di Cosimo F; Fioravanti G; Mannucci E; Vendemiale G; Serviddio G
    J Viral Hepat; 2019 Nov; 26(11):1249-1256. PubMed ID: 31243849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Diagnosis and the Holy Grail.
    Applegate TL; Fajardo E; Sacks JA
    Infect Dis Clin North Am; 2018 Jun; 32(2):425-445. PubMed ID: 29778264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.